EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective Monocentric Analysis of Carmustine Wafer Implantation in Recurrent Glioblastoma: Impact on Survival and Key Prognostic Factors

Naomi Houedjissin, Franziska Staub-Bartelt iD, Michael Sabel, Julia Steinmann, Hannah Fischer iD, Marion Rapp iD

Current Oncology · 22.04.2026 · 33 (5) · 238

DOI: 10.3390/curroncol33050238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 22.04.2026. Verfasst von Naomi Houedjissin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Düsseldorf, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Carmustine, Glioblastoma, Neoplasm Recurrence, Local, Brain Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heinrich-Heine University, Heinrich-Heine University Düsseldorf.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The implantation of biodegradable carmustine (BCNU) wafers is a treatment option for recurrent high-grade glioma (HGG), but its efficacy is debated. We evaluated its impact on overall survival (OS) and survival after recurrence (SAR) considering recurrence timing after first-line treatment.

Methods

In this single-center retrospective study, we analyzed patients who underwent surgery for glioblastoma (GBM) recurrence following initial diagnosis (pre- and post-WHO classification 2016) between 2007 and 2022. All patients received standard first-line therapy, including maximal safe resection, radiotherapy with concomitant temozolomide, and adjuvant temozolomide. Recurrent GBM treatment involves resection, with or without adjuvant chemo- and/or radiotherapy. Patients who received carmustine wafer implantation (CWI) during resection were compared to those without wafer placement. Recurrences were classified by timing relative to first-line therapy: (1) post-radiochemotherapy, pre-adjuvant temozolomide; (2) during adjuvant temozolomide; (3) during prolonged temozolomide; (4) >1 month after completion of all therapy. Primary endpoints were OS and SAR, with prognostic factors analyzed.

Results

A total of 176 patients were enrolled, with 59.7% (105/176) receiving CWI. Recurrence treatment included surgery without adjuvant therapy in 23.3% (41/176) of cases (26.7% of CWI+ and 18.3% of CWI−), adjuvant chemotherapy in 39.8% (70/176) (41% of CWI+ and 38% of CWI−), radiotherapy in 7.4% (13/176) (7.6% of CWI+ and 7% of CWI−), and combined radiochemotherapy in 29.5% (52/176) (24.8% of CWI+ and 36.6% of CWI−). No significant differences were found between groups in age (p = 0.684), residual tumor volume after initial (p = 0.988) or recurrence surgery (p = 0.356), MGMT status (p = 0.766) and KPS post 1st-line-therapy (p = 0.833). Median OS was 20 months [range 18–24] for CWI+ and 22 months [range 20–27] for CWI− (p = 0.487). The median SAR was 10 months [range 8–12] for CWI+ and 12 months [range 10–13] for CWI− (p = 0.252). Later recurrence (type 4) significantly correlated with prolonged OS (HR 0.16, 95% CI: 0.04–0.66, p = 0.011). Age (p < 0.001), MGMT methylation (p = 0.017), and smaller residual tumor volume post-recurrence surgery (p = 0.008) were also associated with longer survival.

Conclusions

CWI did not significantly improve OS or SAR in recurrent GBM patients. However, younger age, MGMT methylation, smaller residual tumor volume, and later recurrence were linked to better survival outcomes, underscoring their prognostic importance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarmustineGlioblastomaNeoplasm Recurrence, LocalBrain NeoplasmsAntineoplastic Agents, AlkylatingHumansRetrospective StudiesFemalePrognosisMaleMiddle AgedAdultAgedDrug Implants

Stichwörter der Autor:innen

carmustine waferglioblastomahigh-grade gliomalocal chemotherapyrecurrence

Substanzen

CarmustineAntineoplastic Agents, AlkylatingDrug Implants

Autor:innen und Institutionen

  • Department of Neurosurgery, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.
  • Faculty of Medicine, Heinrich-Heine University, 40225 Düsseldorf, Germany.
  • Department of Neurosurgery, University Hospital Giessen, 35392 Giessen, Germany.
  • Brain Cancer Center, Beta Clinic, 53127 Bonn, Germany.
  • Department of Neurosurgery, Sana Clinic, 47055 Duisburg, Germany.
  • Evangelisches Klinikum Bethel, 33615 Bielefeld, Germany.

ORCID-Profile: Franziska Staub-Bartelt, Hannah Fischer, Marion Rapp

Förderung

  • Heinrich-Heine University
  • Heinrich-Heine University Düsseldorf

Zitieren

APA

Houedjissin, N., Staub-Bartelt, F., Sabel, M., Steinmann, J., Fischer, H., & Rapp, M. (2026). Retrospective Monocentric Analysis of Carmustine Wafer Implantation in Recurrent Glioblastoma: Impact on Survival and Key Prognostic Factors. Current Oncology, 33(5), 238. https://doi.org/10.3390/curroncol33050238

Vancouver

Houedjissin N, Staub-Bartelt F, Sabel M, Steinmann J, Fischer H, Rapp M. Retrospective Monocentric Analysis of Carmustine Wafer Implantation in Recurrent Glioblastoma: Impact on Survival and Key Prognostic Factors. Current Oncology. 2026;33(5):238. doi:10.3390/curroncol33050238

BibTeX
@article{Houedjissin2026,
  author = {Houedjissin, Naomi and Staub-Bartelt, Franziska and Sabel, Michael and Steinmann, Julia and Fischer, Hannah and Rapp, Marion},
  title = {Retrospective Monocentric Analysis of Carmustine Wafer Implantation in Recurrent Glioblastoma: Impact on Survival and Key Prognostic Factors},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {238},
  doi = {10.3390/curroncol33050238}
}
Kostenlos starten →